Pertussis

FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1

Retrieved on: 
Monday, January 3, 2022

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis.

Key Points: 
  • ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis.
  • BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development.
  • Fast Track provides opportunities for frequent Company interactions with the FDA and the potential for accelerated approval and priority review.
  • BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough).

ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial

Retrieved on: 
Friday, December 17, 2021

ILiAD Biotechnologies announces enrollment of the first participants in the SUPER Trial (Standing Up to PERtussis) the first study in school-age children of BPZE1, a live attenuated intranasal pertussis vaccine.

Key Points: 
  • ILiAD Biotechnologies announces enrollment of the first participants in the SUPER Trial (Standing Up to PERtussis) the first study in school-age children of BPZE1, a live attenuated intranasal pertussis vaccine.
  • The SUPER Trial will allow evaluation of BPZE1 in a cohort of participants that were primed with aPV during childhood.
  • BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough).
  • ILiAD Biotechnologies ( http://www.iliadbio.com ) is a privately held, clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis.

ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis

Retrieved on: 
Wednesday, September 29, 2021

Pertactin (PRN) is a highly immunogenic virulence factor secreted by Bordetella pertussis (B. pertussis).

Key Points: 
  • Pertactin (PRN) is a highly immunogenic virulence factor secreted by Bordetella pertussis (B. pertussis).
  • PHE performed testing on serum samples from BPZE1 and Boostrix vaccinated subjects, which were analyzed in a blinded fashion.
  • Furthermore, this preliminary set of samples from the Boostrix vaccinated group demonstrated no subjects with > 2x fold rise in SBA titres against PRN(-) B. pertussis (N = 0/17).
  • Its lead candidate, BPZE1, is the most advanced next generation vaccine for the prevention of pertussis (whooping cough), a serious disease caused by Bordetella pertussis.

Global Preventive Vaccines Market (2020 to 2030) - Featuring Bio Farma, Emergent BioSolutions & GC Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 11, 2020

This report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain.

Key Points: 
  • This report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain.
  • Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases.
  • In fact, recent immunization records indicate that more than 115 million children are immunized against diphtheria, tetanus and pertussis annually.
  • Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly.

Diphtheria, Pertussis, and Tetanus Vaccine (DTP) Market to Reach $7.05 Bn, Globally, by 2027 at 5.1% CAGR: Allied Market Research

Retrieved on: 
Tuesday, June 9, 2020

According to the report, the global diphtheria, pertussis, and tetanus vaccine (DTP) market garnered $4.75 billion in 2019, and is estimated to reach $7.05 billion by 2027, registering a CAGR of 5.1% from 2020 to 2027.

Key Points: 
  • According to the report, the global diphtheria, pertussis, and tetanus vaccine (DTP) market garnered $4.75 billion in 2019, and is estimated to reach $7.05 billion by 2027, registering a CAGR of 5.1% from 2020 to 2027.
  • However, high production cost of vaccine and inadequate access to vaccines in under developed countries hinder the market growth.
  • The coronavirus outbreak has not much affected the global diphtheria, pertussis, and tetanus vaccine (DTP) market.
  • This is attributed to growth in research and development (R&D) activities and increase in demand for DTP vaccine among infants.

Diphtheria, Pertussis, and Tetanus Vaccine (DTP) Market to Reach $7.05 Bn, Globally, by 2027 at 5.1% CAGR: Allied Market Research

Retrieved on: 
Tuesday, June 9, 2020

According to the report, the global diphtheria, pertussis, and tetanus vaccine (DTP) market garnered $4.75 billion in 2019, and is estimated to reach $7.05 billion by 2027, registering a CAGR of 5.1% from 2020 to 2027.

Key Points: 
  • According to the report, the global diphtheria, pertussis, and tetanus vaccine (DTP) market garnered $4.75 billion in 2019, and is estimated to reach $7.05 billion by 2027, registering a CAGR of 5.1% from 2020 to 2027.
  • However, high production cost of vaccine and inadequate access to vaccines in under developed countries hinder the market growth.
  • The coronavirus outbreak has not much affected the global diphtheria, pertussis, and tetanus vaccine (DTP) market.
  • This is attributed to growth in research and development (R&D) activities and increase in demand for DTP vaccine among infants.

The Global Respiratory Disease Vaccine Market is expected to grow from USD 18,236.13 Million in 2018 to USD 25,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.75%

Retrieved on: 
Thursday, May 14, 2020

On the basis of Disease Type, the Global Respiratory Disease Vaccine Market is studied across Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Measles, Pertussis, and Pneumonia.

Key Points: 
  • On the basis of Disease Type, the Global Respiratory Disease Vaccine Market is studied across Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Measles, Pertussis, and Pneumonia.
  • On the basis of Vaccine, the Global Respiratory Disease Vaccine Market is studied across DTaP, Haemophilus Influenzae Type B (HIB), MMR, PPSV23, and Respiratory Syncytial Virus (RSV).
  • What are the factors that affect the growth in the Global Respiratory Disease Vaccine Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Respiratory Disease Vaccine Market?

Global Vaccine Market Outlook Amid COVID-19 Outbreak, 2020-2024 - Presents Worldwide Vaccine Players by Market Share, Major M&A Deals, Vaccine Pipelines; Vaccines in Pipelines for COVID-19

Retrieved on: 
Thursday, April 23, 2020

3.1.2 Global Vaccine Market by Disease (Streptococcus Pneumonia, Diphtheria, Tetanus and Pertussis (DTP), Influenza, Cancer, Human Papillomavirus (HPV), Neisseria Meningitides, Measles, Mumps, and Rubella (MMR), Hepatitis, Rotavirus, Varicella, and Others)

Key Points: 
  • 3.1.2 Global Vaccine Market by Disease (Streptococcus Pneumonia, Diphtheria, Tetanus and Pertussis (DTP), Influenza, Cancer, Human Papillomavirus (HPV), Neisseria Meningitides, Measles, Mumps, and Rubella (MMR), Hepatitis, Rotavirus, Varicella, and Others)
    3.1.3 Global Vaccine Market by Type (Recombinant/Conjugate/Subunit vaccine, Inactivated vaccine, Live-attenuated vaccine, and Toxoid vaccine)
    3.1.5 Global Vaccine Market by Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)
    4.1 North America Vaccine Market: An Analysis
    4.3 Asia Pacific Vaccine Market: An Analysis
    4.4 Latin America Vaccine Market: An Analysis
    4.5 Middle East and Africa Vaccine Market: An Analysis
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

AJ Vaccines To Develop Vaccine for COVID-19

Retrieved on: 
Friday, March 6, 2020

This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the current global challenge of coronavirus COVID-19, says Dr Tabassum Khan, Chairman to AJ Vaccines.

Key Points: 
  • This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the current global challenge of coronavirus COVID-19, says Dr Tabassum Khan, Chairman to AJ Vaccines.
  • Our employees are aware of the current challenges and are dedicated to finding solutions to the COVID-19 challenge with state-of-the-art technology, says Jesper Helmuth Larsen, CEO AJ Vaccines.
  • Modern antigen technology allows for the production of vaccines combining high protection with a low reactogenicity and favorable safety profile as compared to some of the more traditional vaccines.
  • AJ Vaccines Group based in Copenhagen Denmark develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough) and polio.

Global Vaccine Market - One of Public Health's Most Effective Interventions: Infinium Global Research

Retrieved on: 
Wednesday, March 4, 2020

Rising Prevalence of viral diseases is anticipated to promote the demand for vaccine market.

Key Points: 
  • Rising Prevalence of viral diseases is anticipated to promote the demand for vaccine market.
  • Growing awareness of immunization and its benefits in developing markets is steadily driving the global vaccine market growth.
  • Based on the type the vaccine market is further sub-segmented into conjugate, recombinant, inactivated, combination, attenuated and others.
  • Owing to the Increasing Demand from Its Densely Populated Countries
    Geographically the vaccine market is segmented into North America, Europe, APAC and RoW.